EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

Clinical characterization of cutaneous mucormycosis in patients receiving Bruton tyrosine kinase inhibitor therapy with Ibrutinib: A new case report and comparative discussion

Borja González Rodríguez, Jorge Arroyo Andrés, Alfonso Gotor Rivera, Ana Pérez de Ayala Balzola, José Luis Rodríguez Peralto, Concepción Postigo Llorente

Enfermedades infecciosas y microbiologia clinica (English ed.) · 2026

DOI: 10.1016/j.eimce.2026.503201 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Enfermedades infecciosas y microbiologia clinica (English ed.), 2026. Verfasst von Borja González Rodríguez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain. Electronic address: borjasturias@hotmail.com. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Dermatomycoses, Mucormycosis, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Mucormycosis are invasive fungal infections caused by fungi of the order Mucorales that classically affect profoundly immunosuppressed patients. Recently, cases have emerged in patients receiving Bruton tyrosine kinase inhibitors like Ibrutinib, used for chronic lymphocytic leukemia (CLL). METHODS: We report a 58-year-old man with CLL on Ibrutinib and Venetoclax who developed a rapidly progressing necrotic ulcer on his leg after minor trauma. Histopathology revealed angioinvasive, non-septate hyphae; Rhizopus spp. was confirmed by culture. He was treated with surgical debridement, liposomal amphotericin B, and isavuconazole, with good outcome. We also reviewed published cases of cutaneous mucormycosis in Ibrutinib-treated patients. RESULTS: Including our case, seven patients were identified. Most presented with single necrotic limb lesions after minor trauma. Median age was 69.5 years; median Ibrutinib exposure was 3 years. Liposomal amphotericin B was the most used antifungal; surgery was performed in over half of the patients. CONCLUSIONS: Cutaneous mucormycosis is an emerging complication in Ibrutinib-treated patients. Early diagnosis and combined antifungal and surgical treatment are crucial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseDermatomycosesMucormycosisTyrosine Kinase InhibitorsAntineoplastic AgentsHumansMaleMiddle AgedAdenineAmphotericin BAntifungal AgentsDebridementLeukemia, Lymphocytic, Chronic, B-CellNitrilesPiperidinesPyrazolesPyrimidinesRhizopusSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

Chronic lymphocytic leukemiaIbrutinibInfecciones fúngicas oportunistasInhibidor de la tirosina quinasaLeucemia linfática crónicaMucormicosisMucormycosisOpportunistic fungal infectionsTyrosine kinase inhibitors

Substanzen

AdenineAgammaglobulinaemia Tyrosine KinaseAmphotericin BAntifungal AgentsBTK protein, humanibrutinibliposomal amphotericin BNitrilesPiperidinesPyrazoles

Autor:innen und Institutionen

  • Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain. Electronic address: borjasturias@hotmail.com.
  • Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Department of Microbiology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Department of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain.

Zitieren

APA

González Rodríguez, B., Arroyo Andrés, J., Gotor Rivera, A., Pérez de Ayala Balzola, A., Rodríguez Peralto, J. L., & Postigo Llorente, C. (2026). Clinical characterization of cutaneous mucormycosis in patients receiving Bruton tyrosine kinase inhibitor therapy with Ibrutinib: A new case report and comparative discussion. Enfermedades infecciosas y microbiologia clinica (English ed.). https://doi.org/10.1016/j.eimce.2026.503201

Vancouver

González Rodríguez B, Arroyo Andrés J, Gotor Rivera A, Pérez de Ayala Balzola A, Rodríguez Peralto JL, Postigo Llorente C. Clinical characterization of cutaneous mucormycosis in patients receiving Bruton tyrosine kinase inhibitor therapy with Ibrutinib: A new case report and comparative discussion. Enfermedades infecciosas y microbiologia clinica (English ed.). 2026. doi:10.1016/j.eimce.2026.503201

BibTeX
@article{GonzlezRodrguez2026,
  author = {González Rodríguez, Borja and Arroyo Andrés, Jorge and Gotor Rivera, Alfonso and Pérez de Ayala Balzola, Ana and Rodríguez Peralto, José Luis and Postigo Llorente, Concepción},
  title = {Clinical characterization of cutaneous mucormycosis in patients receiving Bruton tyrosine kinase inhibitor therapy with Ibrutinib: A new case report and comparative discussion},
  journal = {Enfermedades infecciosas y microbiologia clinica (English ed.)},
  year = {2026},
  doi = {10.1016/j.eimce.2026.503201}
}
Kostenlos starten →